Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAYNIER MOYA

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1124288980
CMS profile
278302
Location
PEMBROKE PINES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,741.44

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,741.44 2

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Chiesi USA, Inc. $1,741.44 2

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAYNIER MOYA

NPI 1124288980 · CMS profile ID 278302

Allopathic & Osteopathic Physicians / Internal Medicine

PEMBROKE PINES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124288980?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAYNIER MOYA, NPI 1124288980, CMS profile ID 278302. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124288980?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JAYNIER MOYA, NPI 1124288980, CMS profile ID 278302. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124288980?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JAYNIER MOYA, NPI 1124288980, CMS profile ID 278302, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1124288980?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $1,741.44 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Chiesi USA, Inc. $870.7201/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050859851 CMS
Chiesi USA, Inc. $870.7201/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051592383 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $128.50 2
PY2023 $1,741.44 2
PY2025 $15.30 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,567,242.14 108
PY2024 Recipient $1,161.49 6
PY2024 Principal investigator $5,059,140.87 296
PY2023 Recipient $2,506.25 1
PY2023 Principal investigator $14,127,127.37 743
PY2022 Recipient $24,618.00 1
PY2022 Principal investigator $15,001,316.81 131
PY2021 Principal investigator $6,255,399.36 48
PY2020 Principal investigator $653,923.11 62
PY2019 Principal investigator $748,551.83 218

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

744 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $19,125.00 12/21/2023 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986110419
Principal investigator 1 ModernaTX, Inc. $700.00 12/20/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748843
Principal investigator 1 SANOFI US SERVICES INC. $15,720.00 12/18/2023 Non-covered Recipient Entity
Pines Care Research Center Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study No dispute reported 06/30/2026 1035958239
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 12/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1035791071
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 12/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1035791464
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 12/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1035791477
Principal investigator 1 Bavarian Nordic A/S $1,114,292.70 12/13/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724395
Principal investigator 1 Chiesi USA, Inc. $49,071.00 12/13/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051619255
Principal investigator 1 SANOFI US SERVICES INC. $17,678.00 12/11/2023 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1035958175
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 11/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1035791045
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 11/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1035791369
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 11/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1035791385
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 11/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1035791397
Principal investigator 1 Janssen Research & Development, LLC $15,300.00 11/29/2023 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986110429
Principal investigator 1 Bavarian Nordic A/S $1,500.00 11/28/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724389
Principal investigator 1 Bavarian Nordic A/S $339.00 11/28/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724583
Principal investigator 1 ModernaTX, Inc. $1,800.00 11/22/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748797
Principal investigator 1 PFIZER INC. $18,190.00 11/22/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045875903
Principal investigator 1 Bavarian Nordic A/S $220,106.00 11/17/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724371
Principal investigator 1 Bavarian Nordic A/S $70,000.00 11/17/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724589
Principal investigator 1 ModernaTX, Inc. $51.60 11/15/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748295
Principal investigator 1 ModernaTX, Inc. $103.20 11/15/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748301
Principal investigator 1 ModernaTX, Inc. $96.75 11/15/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748375
Principal investigator 1 ModernaTX, Inc. $64.50 11/15/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748405
Principal investigator 1 ModernaTX, Inc. $51.60 11/15/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748465
Principal investigator 1 ModernaTX, Inc. $68.37 11/15/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748469
Principal investigator 1 ModernaTX, Inc. $68.37 11/15/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748531
Principal investigator 1 ModernaTX, Inc. $64.50 11/15/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748563
Principal investigator 1 ModernaTX, Inc. $232.20 11/15/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748569
Principal investigator 1 ModernaTX, Inc. $232.20 11/15/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748599
Principal investigator 1 ModernaTX, Inc. $83.85 11/15/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748629
Principal investigator 1 ModernaTX, Inc. $43.86 11/15/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748633
Principal investigator 1 ModernaTX, Inc. $96.75 11/15/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748733
Principal investigator 1 ModernaTX, Inc. $83.85 11/15/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748739
Principal investigator 1 ModernaTX, Inc. $103.20 11/15/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748803
Principal investigator 1 ModernaTX, Inc. $43.86 11/15/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748809
Principal investigator 1 PFIZER INC. $12,247.30 11/15/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045875887
Principal investigator 1 Janssen Research & Development, LLC $2,120.00 11/14/2023 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986110427
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748145
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748151
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748157
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748163
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748169
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748175
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748181
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748187
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748191
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748199
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748205
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748211
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748217
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748223
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748229
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748235
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748241
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748247
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748253
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748309
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748315
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748321
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748327
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748333
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748339
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748345
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748351
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748357
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748363
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748369
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748381
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748387
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748393
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748399
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748411
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748419
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748423
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748429
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748435
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748441
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748447
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748453
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748459
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748477
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748483
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748489
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748495
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748501
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748507
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748513
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748519
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748525
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748537
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748543
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748551
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748557
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748575
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748581
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748587
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748593
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748605
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748611
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748615
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748623
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748639
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748645
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748651
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748657
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748663
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748669
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748675
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748681
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748687
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748693
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748699
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748705
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748709
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748715
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748721
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748727
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748745
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748751
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748757
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748763
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748769
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748775
Principal investigator 1 ModernaTX, Inc. $1,600.06 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748779
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748785
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748791
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748815
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748821
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748825
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748833
Principal investigator 1 ModernaTX, Inc. $1,835.74 11/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748839
Principal investigator 1 SANOFI US SERVICES INC. $40,167.00 11/14/2023 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1035958103
Principal investigator 1 PFIZER INC. $4,300.00 11/10/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 1 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF SELFAMPLIFYING RNA VACCINE PREPARATIONS AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046390701
Principal investigator 1 Janssen Research & Development, LLC $43,240.00 11/08/2023 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986110425
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 11/08/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1035791021
Principal investigator 1 Chiesi USA, Inc. $43,527.00 11/06/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051616157
Principal investigator 1 Chiesi USA, Inc. $22,032.00 11/06/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051616167
Principal investigator 1 Janssen Research & Development, LLC $480.00 11/06/2023 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986110423
Principal investigator 1 Chiesi USA, Inc. $6,665.19 11/01/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051615627
Principal investigator 1 Chiesi USA, Inc. $1,273.19 11/01/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051615635
Principal investigator 1 Chiesi USA, Inc. $6,488.94 11/01/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051615645
Principal investigator 1 Chiesi USA, Inc. $397.50 11/01/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051615655
Principal investigator 1 Chiesi USA, Inc. $2,652.69 11/01/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051615665
Principal investigator 1 Chiesi USA, Inc. $397.50 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614155
Principal investigator 1 Chiesi USA, Inc. $6,488.94 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614163
Principal investigator 1 Chiesi USA, Inc. $1,273.19 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614173
Principal investigator 1 Chiesi USA, Inc. $2,652.69 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614185
Principal investigator 1 Chiesi USA, Inc. $2,652.69 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614195
Principal investigator 1 Chiesi USA, Inc. $1,882.69 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614203
Principal investigator 1 Chiesi USA, Inc. $1,882.69 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614211
Principal investigator 1 Chiesi USA, Inc. $1,882.69 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614223
Principal investigator 1 Chiesi USA, Inc. $1,273.19 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614231
Principal investigator 1 Chiesi USA, Inc. $2,652.69 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614241
Principal investigator 1 Chiesi USA, Inc. $1,273.19 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614251
Principal investigator 1 Chiesi USA, Inc. $1,882.69 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614261
Principal investigator 1 Chiesi USA, Inc. $1,882.69 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614271
Principal investigator 1 Chiesi USA, Inc. $2,652.69 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614281
Principal investigator 1 Chiesi USA, Inc. $1,882.69 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614293
Principal investigator 1 Chiesi USA, Inc. $1,882.69 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614303
Principal investigator 1 Chiesi USA, Inc. $2,652.69 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614313
Principal investigator 1 Chiesi USA, Inc. $1,882.69 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614325
Principal investigator 1 Chiesi USA, Inc. $1,273.19 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614335
Principal investigator 1 Chiesi USA, Inc. $2,652.69 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614347
Principal investigator 1 Chiesi USA, Inc. $2,652.69 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614357
Principal investigator 1 Chiesi USA, Inc. $6,665.19 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614365
Principal investigator 1 Chiesi USA, Inc. $1,273.19 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614375
Principal investigator 1 Chiesi USA, Inc. $1,882.69 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614383
Principal investigator 1 Chiesi USA, Inc. $6,488.94 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614395
Principal investigator 1 Chiesi USA, Inc. $1,273.19 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614403
Principal investigator 1 Chiesi USA, Inc. $6,665.19 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614413
Principal investigator 1 Chiesi USA, Inc. $6,665.19 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614421
Principal investigator 1 Chiesi USA, Inc. $1,882.69 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614433
Principal investigator 1 Chiesi USA, Inc. $6,488.94 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614445
Principal investigator 1 Chiesi USA, Inc. $6,488.94 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614453
Principal investigator 1 Chiesi USA, Inc. $1,273.19 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614465
Principal investigator 1 Chiesi USA, Inc. $6,488.94 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614475
Principal investigator 1 Chiesi USA, Inc. $1,882.69 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614485
Principal investigator 1 Chiesi USA, Inc. $1,882.69 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614493
Principal investigator 1 Chiesi USA, Inc. $1,273.19 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614503
Principal investigator 1 Chiesi USA, Inc. $6,488.94 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614513
Principal investigator 1 Chiesi USA, Inc. $2,652.69 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614521
Principal investigator 1 Chiesi USA, Inc. $1,273.19 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614531
Principal investigator 1 Chiesi USA, Inc. $397.50 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614541
Principal investigator 1 Chiesi USA, Inc. $6,488.94 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614551
Principal investigator 1 Chiesi USA, Inc. $2,652.69 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614559
Principal investigator 1 Chiesi USA, Inc. $1,882.69 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614567
Principal investigator 1 Chiesi USA, Inc. $1,882.69 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614577
Principal investigator 1 Chiesi USA, Inc. $6,488.94 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614587
Principal investigator 1 Chiesi USA, Inc. $6,488.94 10/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051614595
Principal investigator 1 Janssen Research & Development, LLC $305.00 10/28/2023 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986110421
Principal investigator 1 PFIZER INC. $23,625.00 10/24/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045872859
Principal investigator 1 Chiesi USA, Inc. $62,184.00 10/20/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051612117
Principal investigator 1 SANOFI US SERVICES INC. $37,322.00 10/16/2023 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1035957943
Principal investigator 1 Bavarian Nordic A/S $384,467.40 10/13/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724497
Principal investigator 1 Janssen Research & Development, LLC $132,785.00 09/29/2023 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986110409
Principal investigator 1 PFIZER INC. $750.00 09/21/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045880447
Principal investigator 1 Bavarian Nordic A/S $1,000.00 09/14/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724317
Principal investigator 1 Bavarian Nordic A/S $19,000.00 09/14/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724341
Principal investigator 1 Bavarian Nordic A/S $8,320.00 09/14/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724377
Principal investigator 1 Bavarian Nordic A/S $8,000.00 09/14/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724595
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 09/13/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1035790983
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 09/13/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1035791109
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 09/13/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1035791121
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 09/13/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1035791133
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 09/13/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1035791145
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 09/13/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1035791157
Principal investigator 1 SANOFI US SERVICES INC. $30,538.00 09/11/2023 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1035957775
Principal investigator 1 ModernaTX, Inc. $5,850.00 09/07/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748055
Principal investigator 1 ModernaTX, Inc. $600.00 09/07/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748091
Principal investigator 1 ModernaTX, Inc. $6,500.00 09/06/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748061
Principal investigator 1 ModernaTX, Inc. $1,800.00 09/06/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748067
Principal investigator 1 ModernaTX, Inc. $1,500.00 09/06/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748073
Principal investigator 1 ModernaTX, Inc. $700.00 09/06/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748079
Principal investigator 1 ModernaTX, Inc. $2,500.00 09/06/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041748085
Principal investigator 1 Janssen Research & Development, LLC $254,320.00 08/31/2023 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986110417
Principal investigator 1 GlaxoSmithKline, LLC. $161,309.88 08/25/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP PHASE II STUDY No dispute reported 06/30/2026 1006204555
Principal investigator 1 SANOFI US SERVICES INC. $21,111.00 08/14/2023 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1035957721
Principal investigator 1 Bavarian Nordic A/S $16,900.00 08/10/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724385
Principal investigator 1 Chiesi USA, Inc. $23,420.00 08/10/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051604545
Principal investigator 1 Janssen Research & Development, LLC $204,530.00 08/08/2023 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986110415
Principal investigator 1 PFIZER INC. $11,960.00 08/08/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 1 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF SELFAMPLIFYING RNA VACCINE PREPARATIONS AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046429187
Principal investigator 1 PFIZER INC. $16,848.00 08/05/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 1 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF SELFAMPLIFYING RNA VACCINE PREPARATIONS AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046372013
Principal investigator 1 PFIZER INC. $31,715.00 07/26/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045880491
Principal investigator 1 Chiesi USA, Inc. $6,488.94 07/19/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051600737
Principal investigator 1 Chiesi USA, Inc. $1,882.69 07/19/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051600743
Principal investigator 1 Chiesi USA, Inc. $1,882.69 07/19/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051600753
Principal investigator 1 Chiesi USA, Inc. $6,488.94 07/19/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051600763
Principal investigator 1 Chiesi USA, Inc. $6,488.94 07/19/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051600769
Principal investigator 1 Chiesi USA, Inc. $1,273.19 07/19/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051600781
Principal investigator 1 Chiesi USA, Inc. $2,652.69 07/19/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051600789
Principal investigator 1 Chiesi USA, Inc. $2,652.69 07/19/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051600797
Principal investigator 1 Chiesi USA, Inc. $6,488.94 07/19/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051600805
Principal investigator 1 Chiesi USA, Inc. $2,652.69 07/19/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051600815
Principal investigator 1 Chiesi USA, Inc. $1,273.19 07/19/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051600825
Principal investigator 1 Chiesi USA, Inc. $1,273.19 07/19/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051600835
Principal investigator 1 Chiesi USA, Inc. $1,273.19 07/19/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051600845
Principal investigator 1 Chiesi USA, Inc. $2,652.69 07/19/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051600855
Principal investigator 1 Janssen Research & Development, LLC $80,560.00 07/13/2023 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986110413
Principal investigator 1 PFIZER INC. $35,672.00 07/13/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045880477
Principal investigator 1 Bavarian Nordic A/S $56,056.50 07/11/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724517
Principal investigator 1 Janssen Research & Development, LLC $221,225.00 07/10/2023 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986110411
Principal investigator 1 PFIZER INC. $654,834.60 07/06/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045880173
Principal investigator 1 Bavarian Nordic A/S $13,378.50 07/04/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724555
Principal investigator 1 Chiesi USA, Inc. $21,580.00 07/03/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051597977
Principal investigator 1 Bavarian Nordic A/S $8,027.10 06/28/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724415
Principal investigator 1 PFIZER INC. $402,688.00 06/27/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045880191
Principal investigator 1 Bavarian Nordic A/S $65,319.30 06/20/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724451
Principal investigator 1 Bavarian Nordic A/S $95,508.00 06/13/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724505
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792291
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792297
Principal investigator 1 ModernaTX, Inc. $2,787.67 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792305
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792311
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792317
Principal investigator 1 ModernaTX, Inc. $651.15 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792325
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792333
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792339
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792345
Principal investigator 1 ModernaTX, Inc. $651.15 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792353
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792361
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792369
Principal investigator 1 ModernaTX, Inc. $651.15 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792377
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792386
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792395
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792403
Principal investigator 1 ModernaTX, Inc. $2,787.67 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792411
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792421
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792431
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792439
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792447
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792455
Principal investigator 1 ModernaTX, Inc. $2,685.19 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792463
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792473
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792481
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792489
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792497
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792505
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792513
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792521
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792527
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792535
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792541
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792551
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792559
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792567
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792575
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792585
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792593
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792603
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792609
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792617
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792625
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792633
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792641
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792651
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792661
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792667
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792677
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792685
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792695
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792701
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792709
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792715
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792723
Principal investigator 1 ModernaTX, Inc. $651.15 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792731
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792739
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792747
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792755
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792763
Principal investigator 1 ModernaTX, Inc. $2,685.19 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792771
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792779
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792787
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792795
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792803
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792811
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792821
Principal investigator 1 ModernaTX, Inc. $2,685.19 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792829
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792837
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792845
Principal investigator 1 ModernaTX, Inc. $2,787.67 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792853
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792861
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792869
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792935
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792943
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792951
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792959
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792967
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792975
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792983
Principal investigator 1 ModernaTX, Inc. $651.15 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041792991
Principal investigator 1 ModernaTX, Inc. $651.15 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793001
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793009
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793017
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793025
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793031
Principal investigator 1 ModernaTX, Inc. $2,685.19 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793039
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793047
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793057
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793065
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793073
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793081
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793089
Principal investigator 1 ModernaTX, Inc. $2,787.67 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793097
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793105
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793113
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793121
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793129
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793137
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793147
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793155
Principal investigator 1 ModernaTX, Inc. $2,685.19 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793163
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793171
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793179
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793187
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793195
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793203
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793211
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793219
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793227
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793235
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793243
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793251
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793261
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793269
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793275
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793283
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793291
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793299
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793307
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793315
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793321
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793329
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793338
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793345
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793359
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793367
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793375
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793383
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793391
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793399
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793407
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793415
Principal investigator 1 ModernaTX, Inc. $651.15 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793421
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793429
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793441
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793447
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793455
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793463
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793471
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793479
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793489
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793497
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793505
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793513
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793521
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793529
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793539
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793547
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793553
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793561
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793569
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793577
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793585
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793593
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793601
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793609
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793617
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793625
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793635
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793643
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793651
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793657
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793665
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793673
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793681
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793689
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793697
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793705
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793713
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793723
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793731
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793739
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793747
Principal investigator 1 ModernaTX, Inc. $2,787.67 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793755
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793763
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793771
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793779
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793787
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793793
Principal investigator 1 ModernaTX, Inc. $2,787.67 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793801
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793809
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793817
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793825
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793833
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793841
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793849
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793857
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793865
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793873
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793881
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793889
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793897
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793905
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793915
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793923
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793931
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793939
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793947
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793955
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793963
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793971
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793979
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793987
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041793995
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794003
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794011
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794019
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794027
Principal investigator 1 ModernaTX, Inc. $651.15 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794035
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794043
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794051
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794059
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794067
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794075
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794083
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794091
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794099
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794109
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794117
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794125
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794133
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794141
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794149
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794157
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794165
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794173
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794181
Principal investigator 1 ModernaTX, Inc. $651.15 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794189
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794197
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794205
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794213
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794223
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794231
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794237
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794247
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794253
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794261
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794269
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794277
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794287
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794295
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794303
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794311
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794315
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794325
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794335
Principal investigator 1 ModernaTX, Inc. $2,787.67 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794341
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794349
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794357
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794365
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794373
Principal investigator 1 ModernaTX, Inc. $2,685.19 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794381
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794389
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794397
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794407
Principal investigator 1 ModernaTX, Inc. $2,787.67 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794415
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794423
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794431
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794440
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794449
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794457
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794463
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794473
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794479
Principal investigator 1 ModernaTX, Inc. $2,685.19 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794489
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794497
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794505
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794513
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794521
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794529
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794537
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794545
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794555
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794563
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794571
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794579
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794587
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794595
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794603
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794611
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794619
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794627
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794635
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794643
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794651
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794661
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794669
Principal investigator 1 ModernaTX, Inc. $651.15 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794677
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794685
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794695
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794703
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794711
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794719
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794727
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794735
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794743
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794753
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794761
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794769
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794777
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794785
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794793
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794801
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794807
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794817
Principal investigator 1 ModernaTX, Inc. $651.15 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794825
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794833
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794841
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794849
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794857
Principal investigator 1 ModernaTX, Inc. $2,685.19 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794865
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794873
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794881
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794889
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794897
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794905
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794915
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794923
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794931
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794939
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794947
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794955
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794963
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794973
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794981
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794989
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041794997
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795005
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795013
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795021
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795029
Principal investigator 1 ModernaTX, Inc. $2,787.67 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795039
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795047
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795055
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795063
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795073
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795081
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795089
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795097
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795105
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795113
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795121
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795129
Principal investigator 1 ModernaTX, Inc. $651.15 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795137
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795145
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795153
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795161
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795169
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795177
Principal investigator 1 ModernaTX, Inc. $651.15 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795185
Principal investigator 1 ModernaTX, Inc. $651.15 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795193
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795201
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795209
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795217
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795225
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795233
Principal investigator 1 ModernaTX, Inc. $651.15 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795241
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795249
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795257
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795265
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795275
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795279
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795288
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795295
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795307
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795315
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795323
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795331
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795339
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795347
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795355
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795363
Principal investigator 1 ModernaTX, Inc. $2,787.67 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795371
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795379
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795387
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795393
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795405
Principal investigator 1 ModernaTX, Inc. $2,685.19 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795413
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795421
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795429
Principal investigator 1 ModernaTX, Inc. $4,217.10 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795437
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795447
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795455
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795461
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795469
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795477
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795485
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795495
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795503
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795511
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795519
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795527
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795535
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795543
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795551
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795561
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795569
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795577
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795585
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795593
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795601
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795609
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795617
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795625
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795635
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795643
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795651
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795659
Principal investigator 1 ModernaTX, Inc. $651.15 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795667
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795675
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795683
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795691
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795699
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795707
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795715
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795723
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795731
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795739
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795749
Principal investigator 1 ModernaTX, Inc. $2,685.19 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795755
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795763
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795773
Principal investigator 1 ModernaTX, Inc. $749.83 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795781
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795789
Principal investigator 1 ModernaTX, Inc. $17.41 06/12/2023 Non-covered Recipient Entity
PINES CARE MEDICAL CENTER, LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041795797
Principal investigator 1 Bavarian Nordic A/S $117,003.60 06/08/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724543
Principal investigator 1 Chiesi USA, Inc. $26,148.00 06/01/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051595675
Principal investigator 1 Janssen Research & Development, LLC $271,716.00 05/31/2023 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986110407
Principal investigator 1 Bavarian Nordic A/S $77,020.20 05/30/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724403
Principal investigator 1 GlaxoSmithKline, LLC. $10,488.40 05/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP PHASE II STUDY No dispute reported 06/30/2026 1006204567
Principal investigator 1 GlaxoSmithKline, LLC. $2,490.80 05/30/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP PHASE II STUDY No dispute reported 06/30/2026 1006204577
Principal investigator 1 PFIZER INC. $845,859.30 05/26/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045880523
Principal investigator 1 PFIZER INC. $17,525.00 05/26/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 1 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF SELFAMPLIFYING RNA VACCINE PREPARATIONS AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046437053
Principal investigator 1 Bavarian Nordic A/S $50,128.20 05/24/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724433
Principal investigator 1 Bavarian Nordic A/S $122,648.40 05/19/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724465
Principal investigator 1 Janssen Research & Development, LLC $47,470.00 05/17/2023 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986110403
Principal investigator 1 Bavarian Nordic A/S $54,943.20 05/16/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724477
Principal investigator 1 PFIZER INC. $598.00 05/16/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 1 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF SELFAMPLIFYING RNA VACCINE PREPARATIONS AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046525029
Principal investigator 1 Bavarian Nordic A/S $180,604.80 05/09/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724529
Principal investigator 1 PFIZER INC. $277,994.40 05/09/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045880537
Principal investigator 1 Bavarian Nordic A/S $138,899.70 05/03/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724571
Principal investigator 1 Chiesi USA, Inc. $32,220.00 05/01/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051594217
Principal investigator 1 Bavarian Nordic A/S $24,300.00 04/26/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724335
Principal investigator 1 Bavarian Nordic A/S $8,619.00 04/26/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724365
Principal investigator 1 Bavarian Nordic A/S $119,299.50 04/26/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724421
Principal investigator 1 Janssen Research & Development, LLC $362,520.00 04/24/2023 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986110405
Principal investigator 1 PFIZER INC. $361,136.10 04/19/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045880281
Principal investigator 1 Bavarian Nordic A/S $182,378.70 04/18/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724471
Principal investigator 1 Janssen Research & Development, LLC $2,640.00 04/17/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Phase 2b Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Rilematovir JNJ53718678 in Adult Outpatients with Respiratory Syncytial Virus RSV Infection who are at High Risk for RSV related Disease Progression No dispute reported 06/30/2026 986148555
Principal investigator 1 PFIZER INC. $156,589.50 04/15/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 1 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF SELFAMPLIFYING RNA VACCINE PREPARATIONS AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046439924
Principal investigator 1 PFIZER INC. $160,607.20 04/14/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045880627
Principal investigator 1 Bavarian Nordic A/S $128,025.00 04/13/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724511
Principal investigator 1 PFIZER INC. $92,869.40 04/12/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045880613
Principal investigator 1 Chiesi USA, Inc. $56,118.00 04/10/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051593055
Principal investigator 1 ModernaTX, Inc. $166.50 04/06/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041747841
Principal investigator 1 Bavarian Nordic A/S $299,609.10 04/04/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724563
Principal investigator 1 Bavarian Nordic A/S $13,107.00 03/29/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724359
Principal investigator 1 Bavarian Nordic A/S $65,326.50 03/29/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724409
Principal investigator 1 PFIZER INC. $185,294.30 03/24/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045863341
Principal investigator 1 PFIZER INC. $198,790.00 03/23/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045882013
Principal investigator 1 PFIZER INC. $487.50 03/23/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 1 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF SELFAMPLIFYING RNA VACCINE PREPARATIONS AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046461519
Principal investigator 1 Bavarian Nordic A/S $130,550.40 03/21/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724445
Principal investigator 1 SANOFI US SERVICES INC. $14,700.00 03/20/2023 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1035957225
Principal investigator 1 Bavarian Nordic A/S $525,277.80 03/15/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724491
Principal investigator 1 Bavarian Nordic A/S $41,230.00 03/08/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724323
Principal investigator 1 Bavarian Nordic A/S $78,560.00 03/08/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724353
Principal investigator 1 PFIZER INC. $197,091.80 03/08/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045880731
Principal investigator 1 PFIZER INC. $1,950.00 03/04/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 1 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF SELFAMPLIFYING RNA VACCINE PREPARATIONS AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046366531
Principal investigator 1 PFIZER INC. $352,751.60 03/01/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045879467
Principal investigator 1 PFIZER INC. $1,095.00 03/01/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 1 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF SELFAMPLIFYING RNA VACCINE PREPARATIONS AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046447855
Principal investigator 1 PFIZER INC. $145,057.60 02/25/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045863665
Principal investigator 1 Bavarian Nordic A/S $118,718.10 02/22/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724439
Principal investigator 1 PFIZER INC. $82,495.00 02/22/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045880717
Principal investigator 1 Janssen Research & Development, LLC $39,360.00 02/17/2023 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986110401
Principal investigator 1 Bavarian Nordic A/S $195,377.40 02/16/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724483
Principal investigator 1 PFIZER INC. $67,350.00 02/15/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045881045
Principal investigator 1 Chiesi USA, Inc. $93,124.00 02/14/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051591779
Principal investigator 1 Bavarian Nordic A/S $15,000.00 02/09/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724347
Principal investigator 1 Bavarian Nordic A/S $91,713.60 02/09/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724537
Principal investigator 1 PFIZER INC. $4,060.00 02/08/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045881025
Principal investigator 1 Bavarian Nordic A/S $155,688.30 02/02/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724577
Principal investigator 1 Janssen Research & Development, LLC $50,230.00 01/31/2023 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986110397
Principal investigator 1 Janssen Research & Development, LLC $2,475.00 01/31/2023 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986110399
Principal investigator 1 Bavarian Nordic A/S $285,736.50 01/25/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724427
Principal investigator 1 PFIZER INC. $2,105.00 01/25/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045867671
Principal investigator 1 Bavarian Nordic A/S $126,208.80 01/20/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724457
Principal investigator 1 PFIZER INC. $3,042.00 01/14/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 1 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF SELFAMPLIFYING RNA VACCINE PREPARATIONS AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046546815
Principal investigator 1 Bavarian Nordic A/S $3,999.60 01/10/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724523
Recipient Eli Lilly and Company $2,506.25 01/10/2023 Covered Recipient Physician A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) No dispute reported 06/30/2026 1038053157
Principal investigator 1 Bavarian Nordic A/S $13,300.00 01/06/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724329
Principal investigator 1 Bavarian Nordic A/S $465,778.80 01/06/2023 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988724549
Principal investigator 1 Chiesi USA, Inc. $6,876.00 01/05/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051589887
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $407,425.90 01/04/2023 Non-covered Recipient Entity
Pines Care Research Center LLC
Phase II dose finding PoCC in CKD No dispute reported 06/30/2026 1022138597
Principal investigator 1 Eli Lilly and Company $258,562.00 01/03/2023 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) No dispute reported 06/30/2026 1038134433